Views
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting183
May 2019June 2019July 2019August 2019September 2019October 2019November 2019
Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting6210030
Views
Korman_2017_Mod.pdf201
Views
United Kingdom74
United States52
Germany20
Norway14
Ukraine7
Russia5
Poland4
Sweden2
Bosnia and Herzegovina1
China1
Views
Southend70
Sunnyvale13
Oslo12
Woodbridge9
Beverly Hills6
Kiez6
Fairfield5
Indianapolis5
Ann Arbor4
Englewood4